GlassScriptPhysician profile
Adam Michael Tawney
NPI 1962865147
$11,394.70
in general payments reported to CMS, 2019-2025
38 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $23.75 · 2021: $3,383 · 2022: $2,713 · 2023: $983 · 2024: $2,650 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,604 · Travel and Lodging: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,603.91 |
| Travel and Lodging | $1,443.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,156.02 | 2021-2022 | |
| Inari Medical, INC. | $2,598.07 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbott Laboratories | $813.26 | 2021-2025 | Ultreon, Perclose Prostyle, Amplatzer Amulet |
| Boston Scientific Corporation | $579.50 | 2020-2025 | Avvigo Guidance System, Synergy |
| Merck Sharp & Dohme LLC | $297.43 | 2023-2025 | Verquvo |
| Abiomed | $277.71 | 2021-2025 | Impella |
| Portola Pharmaceuticals, LLC | $227.74 | 2019 | |
| Amgen INC. | $181.52 | 2022-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $153.13 | 2024-2025 | Lifevest |
| Shockwave Medical, INC | $151.99 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Alnylam Pharmaceuticals INC. | $151.28 | 2025 | Amvuttra, Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.80 | 2024-2025 | Jardiance |
| Imperative Care, INC | $143.92 | 2023 | Symphony Catheter |
| Kestra Medical Technology Services, INC. | $142.34 | 2024-2025 | Assure Wcd |
| Pfizer INC. | $140.52 | 2024-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $125.44 | 2021-2024 | Xarelto |
| Cardiovascular Systems INC. | $124.34 | 2021 | |
| Esperion Therapeutics, INC. | $116.66 | 2023-2025 | Nexletol |
| Philips North America LLC | $108.69 | 2021 | |
| Terumo Medical Corporation | $100.00 | 2022 | |
| Novo Nordisk INC | $68.61 | 2024-2025 | Wegovy |
| Recor Medical INC | $67.86 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Chiesi USA, INC. | $63.81 | 2024-2025 | Kengreal, Cleviprex |
| Novartis Pharmaceuticals Corporation | $56.05 | 2022-2025 | |
| Edwards Lifesciences Corporation | $50.77 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $47.69 | 2024-2025 | Camzyos |
| Baxter Healthcare | $45.25 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $41.08 | 2024-2025 | Wainua |
| Actelion Pharmaceuticals US, INC. | $33.10 | 2024 | Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $30.20 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $25.00 | 2025 | |
| Daiichi Sankyo INC. | $23.68 | 2024 | Injectafer |
| United Therapeutics Corporation | $22.17 | 2024 | Tyvaso |
| Heartflow, INC. | $21.96 | 2023 | Ffrct |
| Teleflex LLC | $17.16 | 2024 | Trapliner |
| Penumbra, INC. | $16.71 | 2022 | |
| Bridgebio Pharma, INC. | $14.60 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $13.64 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Tawney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.